Continuous venovenous hemodialysis may be effective in digoxin removal in digoxin toxicity: A case report

2020 ◽  
Vol 24 (4) ◽  
Author(s):  
Cenk Gokalp ◽  
Aysun Fatma Dogan ◽  
Guray Aygun ◽  
Ilhan Kurultak ◽  
Sedat Ustundag
2013 ◽  
Vol 35 (8) ◽  
pp. e22-e23 ◽  
Author(s):  
D. Renard ◽  
E. Rubli ◽  
N. Voide ◽  
F.-X. Borruat ◽  
L. Rothuizen

Cureus ◽  
2019 ◽  
Author(s):  
Rachel E Bridwell ◽  
Keith A Baker ◽  
Christopher O Hoyte ◽  
Patrick C Ng
Keyword(s):  

2016 ◽  
Vol 28 (3) ◽  
pp. 297-301 ◽  
Author(s):  
Kathir Yoganathan ◽  
Beth Roberts ◽  
Martyn K Heatley

Drug–drug interactions with corticosteroids, causing Cushing’s syndrome with secondary adrenal suppression, are well known in HIV patients. Corticosteroids are widely prescribed in the HIV-positive population. However, digoxin is rarely used in HIV patients; hence, digoxin toxicity due to drug–drug interaction is not widely recognised. Nevertheless, this practice might change in the future as HIV cohorts of patients are ageing, due to the successful treatment of HIV infection with combination antiretroviral therapy. We report a case of digoxin toxicity in an HIV-positive 51-year-old man, due to a combination of drug–drug interaction and renal impairment. The first case report of digoxin toxicity due to drug–drug interaction with ritonavir in an HIV-positive woman was published in 2003. To the best of our knowledge, no similar case report has since been published in the literature. This case alerts the profession to the importance of drug–drug interaction and highlights the clinical features of digoxin toxicity.


1998 ◽  
Vol 24 (6) ◽  
pp. 683-686
Author(s):  
MEGUMI MORII ◽  
KAZUYUKI UENO ◽  
MITSUTAKA TAKADA ◽  
SHIGEHO TAKARADA ◽  
SHIRO KAMAKURA ◽  
...  

2017 ◽  
Vol 5 (10) ◽  
pp. 921-924
Author(s):  
Dr. Shreya R Patel ◽  
◽  
Dr. Harsha D Makwana ◽  
Dr. Kamlesh P Patel ◽  
Dr. Supriya D Malhotra ◽  
...  

2020 ◽  
Vol 8 (T1) ◽  
pp. 150-153
Author(s):  
Mohammed Hamzah Mezaal ◽  
Hasan Ali Farhan ◽  
Zainab Atiyah Dakhil

BACKGROUND: Since the WHO declaration of COVID-19 being a global pandemic, the population in general and health-care providers, in particular, became under extraordinary pressure that remarkably impacts their decisions at multiple levels as all of us should make decisions quickly while being uncertain in many times. CASE REPORT: We are reporting a 64-year-old lady with a medical history of atrial fibrillation and mitral regurgitation that treated with digoxin and warfarin therapy, she was suspected to be a COVID-19 case and prescribed empirical hydroxychloroquine and azithromycin combination without proper adjustment of her baseline therapy, accordingly she developed adverse effect of this combination in the form of digoxin toxicity and long QT, this case highlights how this unprecedented pandemic affects the decision-making of physicians. CONCLUSION: We should be critical and vigilant in making a decision of prescription or marketing non-evidence-based therapy, and when we are obligated for this decision, we should take all precautions to minimize the adverse effects of these drugs.


2012 ◽  
Vol 16 (4) ◽  
pp. 231-233 ◽  
Author(s):  
Manish Gupta ◽  
Omender Singh ◽  
Sanjay Saxena ◽  
Alka Bhasin ◽  
Archana Chaturvedi
Keyword(s):  

Author(s):  
Saranya Punniyakotti ◽  
Benazeer Begum N

 Context: Digoxin is a commonly used inotropic drug that has a narrow therapeutic range and is monitored poorly for its plasma concentration. It is commonly used in the management of cardiovascular disorders for its inotropic effects. Increased risk of chronic digoxin toxicity among the patients receiving digoxin pharmacotherapy is related to its narrow therapeutic range. Apart from its inotropic properties, it can also produce chronotropic and dromotropic effect. Its serum levels vary due to changes in body weight, age, renal function, hepatic impairment, and concomitant drug administrations. Patients receiving digoxin should be monitored periodically for potential drug interactions, adverse effects, toxicity, and other drug-related problems. Symptoms of digoxin-induced cardiotoxicity are difficult to be identified and may become fatal too. Therapeutic drug monitoring will play a significant role in reducing such drug therapy problems and will ensure safety and efficacy of the given drug. Case Report: We report a case of chronic digoxin toxicity in a 22-year-old male with congestive cardiac failure - Class IV and atrial fibrillation with ventricular bigeminy. Results: Patient’s renal parameters were elevated and among electrolytes, sodium level was decreased and potassium level was increased. A reduction in the volume of the distribution of digoxin, due to impairment of renal function or congestive cardiac failure, might be one of the reasons for digoxin toxicity. Drug therapy problems (DTPs) such as untreated indication, inappropriate drug therapy, potential major drug-drug interactions, and drugs prescribed when contraindicated were observed. Conclusion: Monitoring digoxin drug therapy can bring down the risk of digoxin intoxication.


Sign in / Sign up

Export Citation Format

Share Document